董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John S. McBride | 男 | Director | 71 | 12.31万美元 | 未持股 | 2023-05-01 |
| June Lee | 女 | Director | 57 | 12.56万美元 | 未持股 | 2023-05-01 |
| David Alexandre C. Gros | 男 | Chief Executive Officer, Director | 50 | 111.85万美元 | 未持股 | 2023-05-01 |
| June Lee | 女 | Director | 57 | 未披露 | 未持股 | 2023-05-01 |
| Walter Ogier | 男 | Director | 66 | 12.31万美元 | 未持股 | 2023-05-01 |
| Steven Perrin | 男 | President, Chief Scientific Officer, Director | 58 | 104.96万美元 | 未持股 | 2023-05-01 |
| David Alexandre C. Gros | 男 | Chief Executive Officer, Director | 50 | 未披露 | 未持股 | 2023-05-01 |
| Jan Hillson | 女 | Director | 70 | 10.56万美元 | 未持股 | 2023-05-01 |
| Keith A. Katkin | 男 | Chairman of the Board | 52 | 23.31万美元 | 未持股 | 2023-05-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Paul Little | 男 | Chief Financial Officer | 58 | 105.74万美元 | 未持股 | 2023-05-01 |
| David Alexandre C. Gros | 男 | Chief Executive Officer, Director | 50 | 111.85万美元 | 未持股 | 2023-05-01 |
| Steven Perrin | 男 | President, Chief Scientific Officer, Director | 58 | 104.96万美元 | 未持股 | 2023-05-01 |
| David Alexandre C. Gros | 男 | Chief Executive Officer, Director | 50 | 未披露 | 未持股 | 2023-05-01 |
| Paul Little | 男 | Chief Financial Officer | 59 | 未披露 | 未持股 | 2023-05-01 |
| Bryan Smith | 男 | General Counsel, Corporate Secretary and Chief Compliance Officer | 44 | 未披露 | 未持股 | 2023-05-01 |
董事简历
中英对照 | 中文 | 英文- John S. McBride
-
John S. McBride，他曾一直担任Eledon Pharmaceuticals, Inc.的首席运营官（自2014年2月以来），以及首席财务官（从2014年4月到2014年9月）。加入Eledon Pharmaceuticals, Inc.之前，他曾创立Alliance Life Science Advisors公司（咨询公司，专注于帮助生命科学公司战略规划、业务发展和融资项目），并担任总裁（从2012年3月到2014年2月）。创立Alliance Life Science Advisors公司之前，他曾担任独立顾问（从2009年1月到2012年3月）。此外，他此前曾担任Gloucester Pharmaceuticals公司的执行副总裁兼首席运营官、Pharmacia Corporation的肿瘤学授权部门全球主管、CytoTherapeutics公司的业务运营执行副总裁兼首席财务官、Phytera公司的业务发展和财务主管副总裁、Sparta Pharmaceuticals公司的商业发展副总裁、U.S. Bioscience公司的业务发展副总裁。目前，他担任Intezyne公司的董事会成员。从2008年8月到2013年6月，他曾担任Niiki Pharma公司的董事会成员。他持有the University of Wisconsin的生物化学学士学位和化学工程硕士学位，以及宾夕法尼亚大学沃顿商学院（the Wharton School, University of Pennsylvania）的工商管理硕士学位。
John S. McBride,has been a member of Eledon Pharmaceuticals, Inc. Board since May 2017 and currently serves on Eledon Pharmaceuticals, Inc. nominating and corporate governance committee and serves as the Chair of Eledon Pharmaceuticals, Inc. audit committee. Mr. McBride currently serves as President of Alliance Life Science Advisors, Inc., a consulting firm focused on assisting life science companies with strategic planning, business development and financing projects. Mr. McBride has been active with the firm during various periods over the last thirteen years. From August 2019 until March 2021, Mr. McBride was Chief Financial Officer of Cadent Therapeutics, Inc. Mr. McBride served as Tokai Pharmaceuticals' Chief Operating Officer from February 2014 to May 2017 and as Tokai's Chief Financial Officer from September 2016 to May 2017. Mr. McBride previously served as Tokai's interim Chief Financial Officer from April 2014 until September 2014. Prior to joining Tokai, Mr. McBride founded and served as President of Alliance Life Science Advisors, Inc., where he was active from March 2012 until February 2014 and became active again beginning in June 2017 until August 2019. Prior to founding Alliance Life Science Advisors, Inc., Mr. McBride was an independent consultant from January 2009 until March 2012. In addition, Mr. McBride previously served as Executive Vice President and Chief Operating Officer of Gloucester Pharmaceuticals, Inc., Global Head of Oncology Licensing at Pharmacia Corporation, Executive Vice President, Business Operations and Chief Financial Officer at CytoTherapeutics, Inc., Vice President, Business Development and Treasurer at Phytera, Inc., Vice President, Commercial Development at Sparta Pharmaceuticals, Inc. and Vice President, Business Development at U.S. Bioscience, Inc. Mr. McBride holds a B.S. in Biochemistry and an M.S. in Chemical Engineering from the University of Wisconsin and an M.B.A from the Wharton School, University of Pennsylvania. - John S. McBride，他曾一直担任Eledon Pharmaceuticals, Inc.的首席运营官（自2014年2月以来），以及首席财务官（从2014年4月到2014年9月）。加入Eledon Pharmaceuticals, Inc.之前，他曾创立Alliance Life Science Advisors公司（咨询公司，专注于帮助生命科学公司战略规划、业务发展和融资项目），并担任总裁（从2012年3月到2014年2月）。创立Alliance Life Science Advisors公司之前，他曾担任独立顾问（从2009年1月到2012年3月）。此外，他此前曾担任Gloucester Pharmaceuticals公司的执行副总裁兼首席运营官、Pharmacia Corporation的肿瘤学授权部门全球主管、CytoTherapeutics公司的业务运营执行副总裁兼首席财务官、Phytera公司的业务发展和财务主管副总裁、Sparta Pharmaceuticals公司的商业发展副总裁、U.S. Bioscience公司的业务发展副总裁。目前，他担任Intezyne公司的董事会成员。从2008年8月到2013年6月，他曾担任Niiki Pharma公司的董事会成员。他持有the University of Wisconsin的生物化学学士学位和化学工程硕士学位，以及宾夕法尼亚大学沃顿商学院（the Wharton School, University of Pennsylvania）的工商管理硕士学位。
- John S. McBride,has been a member of Eledon Pharmaceuticals, Inc. Board since May 2017 and currently serves on Eledon Pharmaceuticals, Inc. nominating and corporate governance committee and serves as the Chair of Eledon Pharmaceuticals, Inc. audit committee. Mr. McBride currently serves as President of Alliance Life Science Advisors, Inc., a consulting firm focused on assisting life science companies with strategic planning, business development and financing projects. Mr. McBride has been active with the firm during various periods over the last thirteen years. From August 2019 until March 2021, Mr. McBride was Chief Financial Officer of Cadent Therapeutics, Inc. Mr. McBride served as Tokai Pharmaceuticals' Chief Operating Officer from February 2014 to May 2017 and as Tokai's Chief Financial Officer from September 2016 to May 2017. Mr. McBride previously served as Tokai's interim Chief Financial Officer from April 2014 until September 2014. Prior to joining Tokai, Mr. McBride founded and served as President of Alliance Life Science Advisors, Inc., where he was active from March 2012 until February 2014 and became active again beginning in June 2017 until August 2019. Prior to founding Alliance Life Science Advisors, Inc., Mr. McBride was an independent consultant from January 2009 until March 2012. In addition, Mr. McBride previously served as Executive Vice President and Chief Operating Officer of Gloucester Pharmaceuticals, Inc., Global Head of Oncology Licensing at Pharmacia Corporation, Executive Vice President, Business Operations and Chief Financial Officer at CytoTherapeutics, Inc., Vice President, Business Development and Treasurer at Phytera, Inc., Vice President, Commercial Development at Sparta Pharmaceuticals, Inc. and Vice President, Business Development at U.S. Bioscience, Inc. Mr. McBride holds a B.S. in Biochemistry and an M.S. in Chemical Engineering from the University of Wisconsin and an M.B.A from the Wharton School, University of Pennsylvania.
- June Lee
-
June Lee自2017年2月起担任我们的首席运营官。加入我们之前，她曾任职加州大学旧金山分校（the University of California，San Francisco“；UCSF”；）的教员（2011年4月以来），在那里她曾担任临床和转化科学研究所（the Clinical and Translational Science Institute）的催化剂项目主管，以及医学院教授，并负责在大学促进和支持翻译研究的整体战略和运营。Catalyst是用于治疗学，设备，诊断和数字健康技术的UCSF内部加速器。在加入UCSF之前，Lee博士从2006年到2011年担任Genentech，Inc.早期临床开发的疾病领域负责人，在那里她负责多个治疗领域的所有战略和活动以及早期临床开发小组的员工管理、预算和资源分配。2004年至2006年，李博士担任Genentech，Inc.临床开发小组的医学主任，负责该公司许可产品的临床活动。Lee博士拥有约翰霍普金斯大学（Johns Hopkins University）的化学学士学位和加州大学戴维斯分校（University of California，Davis）的医学博士学位。
June Lee,has been one of Abivax Sa independent directors since July 2023. Dr. Lee has served as a venture partner at 5AM Venture Management, LLC since July 2022. Dr. Lee was most recently Founder and Chief Executive Officer of Esker Therapeutics until September 2021. Dr. Lee previously served as the Executive Vice President and Chief Development Officer of MyoKardia, Inc. from January 2019 to June 2020, and was the Chief Operating Officer from February 2017 until January 2019, and the Chief Development Officer from October 2017 to January 2019. From April 2011 until February 2017, Dr. Lee served on the faculty of the University of California, San Francisco, or UCSF, where she was director of the Catalyst program at the Clinical and Translational Science Institute and a professor in the School of Medicine, and was responsible for overall strategy and operations for enabling and supporting translational research at the university. Catalyst is an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. Prior to UCSF, Dr. Lee was a disease area lead, early clinical development, at Genentech, Inc. from 2006 to 2011, where she was responsible for all strategy and activities as well as management of staff, budget, and resource allocation in the early clinical development group in multiple therapeutic areas. Dr. Lee served as a Medical Director in the clinical development group at Genentech, Inc. from 2004 to 2006, where she was responsible for clinical activities for licensed product of the company. She currently serves on Johns Hopkins University Center for Therapeutic Translation's Advisory Board, serves on the board of directors of Tenaya Therapeutics Inc, Eledon Pharmaceuticals Inc. and GenEdit, is a member of the Scientific Advisory Board for Foresite Labs, and previously served as a member of the board of directors of CinCor Pharma, Inc. Dr. Lee holds a B.A. in chemistry from Johns Hopkins University and an M.D. from the University of California, Davis. - June Lee自2017年2月起担任我们的首席运营官。加入我们之前，她曾任职加州大学旧金山分校（the University of California，San Francisco“；UCSF”；）的教员（2011年4月以来），在那里她曾担任临床和转化科学研究所（the Clinical and Translational Science Institute）的催化剂项目主管，以及医学院教授，并负责在大学促进和支持翻译研究的整体战略和运营。Catalyst是用于治疗学，设备，诊断和数字健康技术的UCSF内部加速器。在加入UCSF之前，Lee博士从2006年到2011年担任Genentech，Inc.早期临床开发的疾病领域负责人，在那里她负责多个治疗领域的所有战略和活动以及早期临床开发小组的员工管理、预算和资源分配。2004年至2006年，李博士担任Genentech，Inc.临床开发小组的医学主任，负责该公司许可产品的临床活动。Lee博士拥有约翰霍普金斯大学（Johns Hopkins University）的化学学士学位和加州大学戴维斯分校（University of California，Davis）的医学博士学位。
- June Lee,has been one of Abivax Sa independent directors since July 2023. Dr. Lee has served as a venture partner at 5AM Venture Management, LLC since July 2022. Dr. Lee was most recently Founder and Chief Executive Officer of Esker Therapeutics until September 2021. Dr. Lee previously served as the Executive Vice President and Chief Development Officer of MyoKardia, Inc. from January 2019 to June 2020, and was the Chief Operating Officer from February 2017 until January 2019, and the Chief Development Officer from October 2017 to January 2019. From April 2011 until February 2017, Dr. Lee served on the faculty of the University of California, San Francisco, or UCSF, where she was director of the Catalyst program at the Clinical and Translational Science Institute and a professor in the School of Medicine, and was responsible for overall strategy and operations for enabling and supporting translational research at the university. Catalyst is an internal UCSF accelerator for therapeutics, devices, diagnostics, and digital health technologies. Prior to UCSF, Dr. Lee was a disease area lead, early clinical development, at Genentech, Inc. from 2006 to 2011, where she was responsible for all strategy and activities as well as management of staff, budget, and resource allocation in the early clinical development group in multiple therapeutic areas. Dr. Lee served as a Medical Director in the clinical development group at Genentech, Inc. from 2004 to 2006, where she was responsible for clinical activities for licensed product of the company. She currently serves on Johns Hopkins University Center for Therapeutic Translation's Advisory Board, serves on the board of directors of Tenaya Therapeutics Inc, Eledon Pharmaceuticals Inc. and GenEdit, is a member of the Scientific Advisory Board for Foresite Labs, and previously served as a member of the board of directors of CinCor Pharma, Inc. Dr. Lee holds a B.A. in chemistry from Johns Hopkins University and an M.D. from the University of California, Davis.
- David Alexandre C. Gros
-
David AlexandreC.Gros，医学博士于2017年1月成为总裁兼首席运营官。在加入Neurocrine之前，他是高级副总裁，首席商务官和首席财务官，也是AlnylamPharmaceuticals，Inc.管理委员会的成员在2015年6月加入Alnylam之前，Gros博士曾于2011年9月至2015年6月担任赛诺菲（Sanofi SA）的执行Vice President兼首席战略官。任职Sanofi公司之前，他曾担任Centerview Partners公司（从2009年到2011年7月）、Merrill Lynch公司（从2006年到2009年）的负责生物技术和制药的投资银行职务，以及McKinsey&Company的管理咨询职务（此前）。Gros博士拥有约翰霍普金斯大学医学院的M.D.，哈佛商学院的M.B.A.和达特茅斯学院的B.A.。
David Alexandre C. Gros,has been a member of Eledon Pharmaceuticals, Inc. Board and the Company's Chief Executive Officer since September 2020. Dr. Gros served as an advisor to Eledon since May 2020. He joined Eledon from Imbria Pharmaceuticals, Inc., a clinical-stage biotechnology company, where from May 2018, he was Co-Founder, Chief Executive Officer and served on its board of directors, including as Chairman. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and of Saint Jean Groupe, S.A., a French manufacturer of pasta products. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College. - David AlexandreC.Gros，医学博士于2017年1月成为总裁兼首席运营官。在加入Neurocrine之前，他是高级副总裁，首席商务官和首席财务官，也是AlnylamPharmaceuticals，Inc.管理委员会的成员在2015年6月加入Alnylam之前，Gros博士曾于2011年9月至2015年6月担任赛诺菲（Sanofi SA）的执行Vice President兼首席战略官。任职Sanofi公司之前，他曾担任Centerview Partners公司（从2009年到2011年7月）、Merrill Lynch公司（从2006年到2009年）的负责生物技术和制药的投资银行职务，以及McKinsey&Company的管理咨询职务（此前）。Gros博士拥有约翰霍普金斯大学医学院的M.D.，哈佛商学院的M.B.A.和达特茅斯学院的B.A.。
- David Alexandre C. Gros,has been a member of Eledon Pharmaceuticals, Inc. Board and the Company's Chief Executive Officer since September 2020. Dr. Gros served as an advisor to Eledon since May 2020. He joined Eledon from Imbria Pharmaceuticals, Inc., a clinical-stage biotechnology company, where from May 2018, he was Co-Founder, Chief Executive Officer and served on its board of directors, including as Chairman. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and of Saint Jean Groupe, S.A., a French manufacturer of pasta products. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.
- June Lee
-
June Lee，自2020年12月起担任Eledon Pharmaceuticals, Inc.董事会成员，目前任职于Eledon制药，Inc.薪酬委员会、提名与公司治理委员会以及TERM3，Inc.科学技术委员会主席。最近，Dr. Lee于2022年7月加入5AM Ventures，担任风险合伙人。2021年2月至2021年11月，Dr. Lee担任Esker Therapeutics，Inc.的创始人兼首席执行官。2017年1月至2020年6月，Dr. Lee担任MyoKardia，Inc.的首席开发官和首席运营官，该公司是一家临床阶段的生物技术公司，专注于精准心血管药物。在MyoKardia，她建立并领导了一个世界级的开发组织，最终该公司于2020年11月被百时美施贵宝以131亿美元收购。在2011年4月至2017年1月加入MyoKardia之前，Lee博士是加州大学旧金山分校医学院的医学教授，在那里她担任转化研究主任，并建立了催化剂计划，这是加州大学旧金山分校治疗、设备、诊断和数字健康早期技术的内部加速器。她还是加州大学药物、设备、发现和开发小组的创始主席。此前，2004年3月至2011年4月，她在基因泰克担任心血管、代谢、呼吸、传染病早期临床开发的治疗领域负责人。Lee博士曾在CinCor Pharma公司董事会任职，直到2023年3月被Astra Zeneca收购。Lee博士目前担任Tenya Therapeutics，Inc.，GenEdit的董事会成员，并担任Foresite Labs的科学顾问委员会成员。李博士在约翰霍普金斯大学完成了化学理学学士学位，在加州大学戴维斯分校医学院完成了医学博士学位，并在加州大学洛杉矶分校和加州大学旧金山分校完成了内科和肺与重症监护的临床培训。
June Lee,has served as a member of Eledon Pharmaceuticals, Inc. Board since December 2020 and currently serves on Eledon Pharmaceuticals, Inc. compensation committee, nomination and corporate governance committee and Chair of Eledon Pharmaceuticals, Inc. science and technology committee. Most recently, Dr. Lee joined 5AM Ventures as venture partner in July 2022. From February 2021 to November 2021, Dr. Lee was founder and Chief Executive Officer at Esker Therapeutics, Inc. From January 2017 until June 2020, Dr. Lee was Chief Development Officer and Chief Operating Officer of MyoKardia, Inc., a clinical stage biotechnology company with a focus on precision cardiovascular medicines. At MyoKardia she built and led a world class development organization culminating in the company's $13.1 billion acquisition by Bristol Myers Squibb in November 2020. Prior to MyoKardia from April 2011 to January 2017, Dr. Lee was Professor of Medicine at UCSF School of Medicine, where she served as Director of Translational Research and built the Catalyst Program, an internal accelerator at UCSF for early-stage technologies in therapeutics, devices, diagnostics, and digital health. She is also the founding chair of the University of California Drug, Device, Discovery and Development Group. Previously, from March 2004 to April 2011, she was therapeutic area head in early clinical development in cardiovascular, metabolism, respiratory, and infectious diseases at Genentech. Dr. Lee served on the board of CinCor Pharma, Inc., until it was acquired by Astra Zeneca in March 2023. Dr. Lee currently serves on the board of Tenya Therapeutics, Inc., GenEdit and serves on the Scientific Advisory Board for Foresite Labs. Dr. Lee completed a Bachelor of Science in chemistry at the Johns Hopkins University, an M.D. at the School of Medicine at University of California, Davis, and her clinical training in internal medicine and pulmonary & critical care at UCLA and UCSF. - June Lee，自2020年12月起担任Eledon Pharmaceuticals, Inc.董事会成员，目前任职于Eledon制药，Inc.薪酬委员会、提名与公司治理委员会以及TERM3，Inc.科学技术委员会主席。最近，Dr. Lee于2022年7月加入5AM Ventures，担任风险合伙人。2021年2月至2021年11月，Dr. Lee担任Esker Therapeutics，Inc.的创始人兼首席执行官。2017年1月至2020年6月，Dr. Lee担任MyoKardia，Inc.的首席开发官和首席运营官，该公司是一家临床阶段的生物技术公司，专注于精准心血管药物。在MyoKardia，她建立并领导了一个世界级的开发组织，最终该公司于2020年11月被百时美施贵宝以131亿美元收购。在2011年4月至2017年1月加入MyoKardia之前，Lee博士是加州大学旧金山分校医学院的医学教授，在那里她担任转化研究主任，并建立了催化剂计划，这是加州大学旧金山分校治疗、设备、诊断和数字健康早期技术的内部加速器。她还是加州大学药物、设备、发现和开发小组的创始主席。此前，2004年3月至2011年4月，她在基因泰克担任心血管、代谢、呼吸、传染病早期临床开发的治疗领域负责人。Lee博士曾在CinCor Pharma公司董事会任职，直到2023年3月被Astra Zeneca收购。Lee博士目前担任Tenya Therapeutics，Inc.，GenEdit的董事会成员，并担任Foresite Labs的科学顾问委员会成员。李博士在约翰霍普金斯大学完成了化学理学学士学位，在加州大学戴维斯分校医学院完成了医学博士学位，并在加州大学洛杉矶分校和加州大学旧金山分校完成了内科和肺与重症监护的临床培训。
- June Lee,has served as a member of Eledon Pharmaceuticals, Inc. Board since December 2020 and currently serves on Eledon Pharmaceuticals, Inc. compensation committee, nomination and corporate governance committee and Chair of Eledon Pharmaceuticals, Inc. science and technology committee. Most recently, Dr. Lee joined 5AM Ventures as venture partner in July 2022. From February 2021 to November 2021, Dr. Lee was founder and Chief Executive Officer at Esker Therapeutics, Inc. From January 2017 until June 2020, Dr. Lee was Chief Development Officer and Chief Operating Officer of MyoKardia, Inc., a clinical stage biotechnology company with a focus on precision cardiovascular medicines. At MyoKardia she built and led a world class development organization culminating in the company's $13.1 billion acquisition by Bristol Myers Squibb in November 2020. Prior to MyoKardia from April 2011 to January 2017, Dr. Lee was Professor of Medicine at UCSF School of Medicine, where she served as Director of Translational Research and built the Catalyst Program, an internal accelerator at UCSF for early-stage technologies in therapeutics, devices, diagnostics, and digital health. She is also the founding chair of the University of California Drug, Device, Discovery and Development Group. Previously, from March 2004 to April 2011, she was therapeutic area head in early clinical development in cardiovascular, metabolism, respiratory, and infectious diseases at Genentech. Dr. Lee served on the board of CinCor Pharma, Inc., until it was acquired by Astra Zeneca in March 2023. Dr. Lee currently serves on the board of Tenya Therapeutics, Inc., GenEdit and serves on the Scientific Advisory Board for Foresite Labs. Dr. Lee completed a Bachelor of Science in chemistry at the Johns Hopkins University, an M.D. at the School of Medicine at University of California, Davis, and her clinical training in internal medicine and pulmonary & critical care at UCLA and UCSF.
- Walter Ogier
-
Walter Ogier，自2020年9月起担任Eledon Pharmaceuticals, Inc.董事会成员，当时他因与Anelixis交易有关而加入董事会。Ogier先生目前在Eledon制药，Inc.审计委员会、薪酬委员会和Eledon制药，Inc.科学与技术委员会任职。Ogier先生在2017年9月至2020年9月期间担任Anelixis的董事长。Ogier先生在开发从药品到医疗设备、干细胞和免疫细胞疗法以及基因疗法等治疗性医疗产品方面拥有30多年的经验。从2016年12月到2017年6月，Ogier先生担任Regenacy Pharmaceuticals，LLC的总裁兼首席执行官，从2016年12月到2020年3月，他是Regenacy Pharmaceuticals的董事会成员。Ogier先生曾于2014年至2020年9月担任Biothera Pharmaceuticals，Inc.的董事会成员，自2016年1月起担任Thetis Pharmaceuticals LLC的董事会成员，于2018年1月至2022年4月担任Nemucore Medical Innovations，Inc.的董事会成员，并于2018年7月担任IRX Therapeutics Inc.的董事会成员，直至2018年11月被Brooklyn Immunotherapeutics LLC收购。2001年至2005年，Ogier先生担任Genetix Pharmaceuticals（现为bluebird bio，纳斯达克：BLUE）总裁、首席执行官兼董事。从2008年到2016年被Calgene Corporation收购，Ogier先生担任Acetylon Pharmaceuticals的总裁、首席执行官和董事。最后，Ogier先生于2005年至2007年担任Arbios Systems，Inc.（OTC：ABOS）的总裁、首席执行官兼董事。Ogier先生于1979年获得威廉姆斯学院的化学文学士学位，并于1987年获得耶鲁大学管理学院的MBA学位。
Walter Ogier,has served as a member of Eledon Pharmaceuticals, Inc. Board since September 2020, when he joined the Board in connection with the Anelixis transaction. Mr. Ogier currently serves on Eledon Pharmaceuticals, Inc. audit committee, compensation committee and Eledon Pharmaceuticals, Inc. science and technology committee. Mr. Ogier served as the Chairman of Anelixis from September 2017 until September 2020. Mr. Ogier has more than 30 years of experience developing therapeutic medical products ranging from pharmaceuticals to medical devices, stem and immune cell therapies, and gene therapies. From December 2016 to June 2017, Mr. Ogier served as President and Chief Executive Officer of Regenacy Pharmaceuticals, LLC and from December 2016 through March 2020, he was a member of Regenacy Pharmaceuticals' board of directors. Mr. Ogier has served on the board of directors of Biothera Pharmaceuticals, Inc. from 2014 through September 2020, on the board of managers of Thetis Pharmaceuticals LLC since January 2016, on the board of directors of Nemucore Medical Innovations, Inc. from January 2018 through April 2022, and on the board of directors of IRX Therapeutics Inc. from July 2018 until its acquisition by Brooklyn Immunotherapeutics LLC in November 2018. From 2001 to 2005, Mr. Ogier served as President, Chief Executive Officer and Director of Genetix Pharmaceuticals (now bluebird bio, Inc., Nasdaq: BLUE). From 2008 until its acquisition by Calgene Corporation in 2016, Mr. Ogier served as President, Chief Executive Officer and Director of Acetylon Pharmaceuticals. Finally, Mr. Ogier served as President, Chief Executive Officer and Director for Arbios Systems, Inc. (OTC: ABOS) from 2005 to 2007. Mr. Ogier received his Bachelor of Arts in Chemistry from Williams College in 1979 and an MBA from Yale School of Management in 1987. - Walter Ogier，自2020年9月起担任Eledon Pharmaceuticals, Inc.董事会成员，当时他因与Anelixis交易有关而加入董事会。Ogier先生目前在Eledon制药，Inc.审计委员会、薪酬委员会和Eledon制药，Inc.科学与技术委员会任职。Ogier先生在2017年9月至2020年9月期间担任Anelixis的董事长。Ogier先生在开发从药品到医疗设备、干细胞和免疫细胞疗法以及基因疗法等治疗性医疗产品方面拥有30多年的经验。从2016年12月到2017年6月，Ogier先生担任Regenacy Pharmaceuticals，LLC的总裁兼首席执行官，从2016年12月到2020年3月，他是Regenacy Pharmaceuticals的董事会成员。Ogier先生曾于2014年至2020年9月担任Biothera Pharmaceuticals，Inc.的董事会成员，自2016年1月起担任Thetis Pharmaceuticals LLC的董事会成员，于2018年1月至2022年4月担任Nemucore Medical Innovations，Inc.的董事会成员，并于2018年7月担任IRX Therapeutics Inc.的董事会成员，直至2018年11月被Brooklyn Immunotherapeutics LLC收购。2001年至2005年，Ogier先生担任Genetix Pharmaceuticals（现为bluebird bio，纳斯达克：BLUE）总裁、首席执行官兼董事。从2008年到2016年被Calgene Corporation收购，Ogier先生担任Acetylon Pharmaceuticals的总裁、首席执行官和董事。最后，Ogier先生于2005年至2007年担任Arbios Systems，Inc.（OTC：ABOS）的总裁、首席执行官兼董事。Ogier先生于1979年获得威廉姆斯学院的化学文学士学位，并于1987年获得耶鲁大学管理学院的MBA学位。
- Walter Ogier,has served as a member of Eledon Pharmaceuticals, Inc. Board since September 2020, when he joined the Board in connection with the Anelixis transaction. Mr. Ogier currently serves on Eledon Pharmaceuticals, Inc. audit committee, compensation committee and Eledon Pharmaceuticals, Inc. science and technology committee. Mr. Ogier served as the Chairman of Anelixis from September 2017 until September 2020. Mr. Ogier has more than 30 years of experience developing therapeutic medical products ranging from pharmaceuticals to medical devices, stem and immune cell therapies, and gene therapies. From December 2016 to June 2017, Mr. Ogier served as President and Chief Executive Officer of Regenacy Pharmaceuticals, LLC and from December 2016 through March 2020, he was a member of Regenacy Pharmaceuticals' board of directors. Mr. Ogier has served on the board of directors of Biothera Pharmaceuticals, Inc. from 2014 through September 2020, on the board of managers of Thetis Pharmaceuticals LLC since January 2016, on the board of directors of Nemucore Medical Innovations, Inc. from January 2018 through April 2022, and on the board of directors of IRX Therapeutics Inc. from July 2018 until its acquisition by Brooklyn Immunotherapeutics LLC in November 2018. From 2001 to 2005, Mr. Ogier served as President, Chief Executive Officer and Director of Genetix Pharmaceuticals (now bluebird bio, Inc., Nasdaq: BLUE). From 2008 until its acquisition by Calgene Corporation in 2016, Mr. Ogier served as President, Chief Executive Officer and Director of Acetylon Pharmaceuticals. Finally, Mr. Ogier served as President, Chief Executive Officer and Director for Arbios Systems, Inc. (OTC: ABOS) from 2005 to 2007. Mr. Ogier received his Bachelor of Arts in Chemistry from Williams College in 1979 and an MBA from Yale School of Management in 1987.
- Steven Perrin
-
Steven Perrin，自2020年9月起担任Eledon Pharmaceuticals, Inc.董事会成员，当时他因与Anelixis交易有关而加入董事会。Perrin博士目前担任Eledon Pharmaceuticals, Inc.总裁兼首席科学官，自2020年9月起担任该职位。从2013年1月到加入Eledon，Perrin博士担任Anelixis Therapeutics Inc.的首席执行官。Perrin博士自2010年6月起担任ALS疗法发展研究所的执行主席。Perrin博士还在2007年1月至2018年8月期间担任ALS疗法发展研究所的首席科学官。2001年11月至2006年12月，任渤健 Idec分子谱系副总监。Perrin博士于1987年获得波士顿学院生物学理学学士学位，并于1994年获得波士顿大学医学院生物化学博士学位。
Steven Perrin,has served as a member of Eledon Pharmaceuticals, Inc. Board since September 2020, when he joined the Board in connection with the Anelixis transaction. Dr. Perrin currently serves as Eledon Pharmaceuticals, Inc. President and Chief Scientific Officer, a position he has held since September 2020. From January 2013 until joining Eledon, Dr. Perrin served as Chief Executive Officer of Anelixis Therapeutics Inc. Dr. Perrin has been Executive Chairman of the ALS Therapy Development Institute since June 2010. Dr. Perrin also served as Chief Scientific Officer for the ALS Therapy Development Institute from January 2007 to August 2018. From November 2001 to December 2006, he served as Associate Director of Molecular Profiling for Biogen Idec. Dr. Perrin received his Bachelor of Science in Biology from Boston College in 1987 and his PhD in Biochemistry from Boston University School of Medicine in 1994. - Steven Perrin，自2020年9月起担任Eledon Pharmaceuticals, Inc.董事会成员，当时他因与Anelixis交易有关而加入董事会。Perrin博士目前担任Eledon Pharmaceuticals, Inc.总裁兼首席科学官，自2020年9月起担任该职位。从2013年1月到加入Eledon，Perrin博士担任Anelixis Therapeutics Inc.的首席执行官。Perrin博士自2010年6月起担任ALS疗法发展研究所的执行主席。Perrin博士还在2007年1月至2018年8月期间担任ALS疗法发展研究所的首席科学官。2001年11月至2006年12月，任渤健 Idec分子谱系副总监。Perrin博士于1987年获得波士顿学院生物学理学学士学位，并于1994年获得波士顿大学医学院生物化学博士学位。
- Steven Perrin,has served as a member of Eledon Pharmaceuticals, Inc. Board since September 2020, when he joined the Board in connection with the Anelixis transaction. Dr. Perrin currently serves as Eledon Pharmaceuticals, Inc. President and Chief Scientific Officer, a position he has held since September 2020. From January 2013 until joining Eledon, Dr. Perrin served as Chief Executive Officer of Anelixis Therapeutics Inc. Dr. Perrin has been Executive Chairman of the ALS Therapy Development Institute since June 2010. Dr. Perrin also served as Chief Scientific Officer for the ALS Therapy Development Institute from January 2007 to August 2018. From November 2001 to December 2006, he served as Associate Director of Molecular Profiling for Biogen Idec. Dr. Perrin received his Bachelor of Science in Biology from Boston College in 1987 and his PhD in Biochemistry from Boston University School of Medicine in 1994.
- David Alexandre C. Gros
-
David Alexandre C. Gros，自2020年9月起担任Eledon Pharmaceuticals, Inc.董事会成员和公司首席执行官。Gros博士自2020年5月起担任Eledon的顾问。他从临床阶段的生物技术公司Imbria Pharmaceuticals，Inc.加入Eledon，从2018年5月起，他担任该公司的联合创始人、首席执行官，并在其董事会任职，包括担任董事长。在加入Imbria之前，Gros博士曾担任Neurocrine Biosciences, Inc.总裁兼首席运营官、Alnylam Pharmaceuticals, Inc.首席业务和首席财务官以及赛诺菲，S.A.首席战略官。在加入赛诺菲TERM0之前，Gros博士曾在Centerview Partners，LLC和Merrill Lynch，Pierce，Fenner & Smith Inc.担任医疗保健投资银行部门的领导职务，并在麦肯锡公司担任医疗保健咨询部门的领导职务。他此前曾在他与人共同创立的生物技术公司Eliem Therapeutics, Inc.和法国面食产品制造商Saint Jean Groupe，S.A.的董事会任职。Gros博士在约翰霍普金斯大学医学院获得医学博士学位，在哈佛商学院获得工商管理硕士学位，在达特茅斯学院获得文学学士学位。
David Alexandre C. Gros,has been a member of Eledon Pharmaceuticals, Inc. Board and the Company's Chief Executive Officer since September 2020. Dr. Gros served as an advisor to Eledon since May 2020. He joined Eledon from Imbria Pharmaceuticals, Inc., a clinical-stage biotechnology company, where from May 2018, he was Co-Founder, Chief Executive Officer and served on its board of directors, including as Chairman. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and of Saint Jean Groupe, S.A., a French manufacturer of pasta products. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College. - David Alexandre C. Gros，自2020年9月起担任Eledon Pharmaceuticals, Inc.董事会成员和公司首席执行官。Gros博士自2020年5月起担任Eledon的顾问。他从临床阶段的生物技术公司Imbria Pharmaceuticals，Inc.加入Eledon，从2018年5月起，他担任该公司的联合创始人、首席执行官，并在其董事会任职，包括担任董事长。在加入Imbria之前，Gros博士曾担任Neurocrine Biosciences, Inc.总裁兼首席运营官、Alnylam Pharmaceuticals, Inc.首席业务和首席财务官以及赛诺菲，S.A.首席战略官。在加入赛诺菲TERM0之前，Gros博士曾在Centerview Partners，LLC和Merrill Lynch，Pierce，Fenner & Smith Inc.担任医疗保健投资银行部门的领导职务，并在麦肯锡公司担任医疗保健咨询部门的领导职务。他此前曾在他与人共同创立的生物技术公司Eliem Therapeutics, Inc.和法国面食产品制造商Saint Jean Groupe，S.A.的董事会任职。Gros博士在约翰霍普金斯大学医学院获得医学博士学位，在哈佛商学院获得工商管理硕士学位，在达特茅斯学院获得文学学士学位。
- David Alexandre C. Gros,has been a member of Eledon Pharmaceuticals, Inc. Board and the Company's Chief Executive Officer since September 2020. Dr. Gros served as an advisor to Eledon since May 2020. He joined Eledon from Imbria Pharmaceuticals, Inc., a clinical-stage biotechnology company, where from May 2018, he was Co-Founder, Chief Executive Officer and served on its board of directors, including as Chairman. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and of Saint Jean Groupe, S.A., a French manufacturer of pasta products. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.
- Jan Hillson
-
Jan Hillson，自2021年7月起担任Eledon Pharmaceuticals, Inc.董事会成员，目前担任Eledon制药，Inc.科学与技术委员会成员。Hillson博士目前担任Provention Bio临床开发高级副总裁，该公司是一家临床阶段上市公司，专注于使人衰弱和危及生命的免疫介导疾病，自2021年11月起担任该职位。在加入Provention之前，Hillson博士是Alpine Immune科学的临床开发高级副总裁。在加入Alpine Immune科学公司之前，Hillson博士是ChemoCentryx药物开发高级副总裁，在此之前，曾在摩蒙塔制药担任临床和转化研究副总裁。在她职业生涯的早期，她曾在ZymoGenetics/Bristol Myers Squibb和Xcyte Therapies担任高级职务。希尔森博士还曾担任哈佛医学院（剑桥健康联盟）临床学院成员、华盛顿大学助理教授、弗吉尼亚梅森医疗中心部门负责人。希尔森医生是一名有执照的风湿病学家，并继续照顾患者。她在斯坦福医学院获得医学博士学位，在加州理工学院获得硕士学位，在斯克里普斯海洋研究所获得海洋化学硕士学位，在密歇根州立大学获得学士学位。
Jan Hillson,has served as a member of Eledon Pharmaceuticals, Inc. Board since July 2021 and currently serves on Eledon Pharmaceuticals, Inc. science and technology committee. Dr. Hillson currently serves as Senior Vice President of Clinical Development at Provention Bio, a clinical stage public company focused on debilitating and life-threatening immune-mediated disease a position held since November 2021. Prior to Provention, Dr. Hillson was Senior Vice President of Clinical Development at Alpine Immune Sciences. Prior to Alpine Immune Sciences, Dr. Hillson was Senior Vice President of Drug Development for ChemoCentryx, and, before that, served as Vice President of Clinical and Translational Research at Momenta Pharmaceuticals. Earlier in her career, she served in senior roles at ZymoGenetics/Bristol Myers Squibb and Xcyte Therapies. Dr, Hillson also served as a member of the Clinical Faculty at Harvard Medical School (Cambridge Health Alliance), Assistant Professor at the University of Washington, and Division Head at Virginia Mason Medical Center. Dr. Hillson is a licensed rheumatologist and continues to care for patients. She received her MD from Stanford School of Medicine, an MS from the California Institute of Technology, an MS in Marine Chemistry from Scripps Institute of Oceanography, and a BS from Michigan State University. - Jan Hillson，自2021年7月起担任Eledon Pharmaceuticals, Inc.董事会成员，目前担任Eledon制药，Inc.科学与技术委员会成员。Hillson博士目前担任Provention Bio临床开发高级副总裁，该公司是一家临床阶段上市公司，专注于使人衰弱和危及生命的免疫介导疾病，自2021年11月起担任该职位。在加入Provention之前，Hillson博士是Alpine Immune科学的临床开发高级副总裁。在加入Alpine Immune科学公司之前，Hillson博士是ChemoCentryx药物开发高级副总裁，在此之前，曾在摩蒙塔制药担任临床和转化研究副总裁。在她职业生涯的早期，她曾在ZymoGenetics/Bristol Myers Squibb和Xcyte Therapies担任高级职务。希尔森博士还曾担任哈佛医学院（剑桥健康联盟）临床学院成员、华盛顿大学助理教授、弗吉尼亚梅森医疗中心部门负责人。希尔森医生是一名有执照的风湿病学家，并继续照顾患者。她在斯坦福医学院获得医学博士学位，在加州理工学院获得硕士学位，在斯克里普斯海洋研究所获得海洋化学硕士学位，在密歇根州立大学获得学士学位。
- Jan Hillson,has served as a member of Eledon Pharmaceuticals, Inc. Board since July 2021 and currently serves on Eledon Pharmaceuticals, Inc. science and technology committee. Dr. Hillson currently serves as Senior Vice President of Clinical Development at Provention Bio, a clinical stage public company focused on debilitating and life-threatening immune-mediated disease a position held since November 2021. Prior to Provention, Dr. Hillson was Senior Vice President of Clinical Development at Alpine Immune Sciences. Prior to Alpine Immune Sciences, Dr. Hillson was Senior Vice President of Drug Development for ChemoCentryx, and, before that, served as Vice President of Clinical and Translational Research at Momenta Pharmaceuticals. Earlier in her career, she served in senior roles at ZymoGenetics/Bristol Myers Squibb and Xcyte Therapies. Dr, Hillson also served as a member of the Clinical Faculty at Harvard Medical School (Cambridge Health Alliance), Assistant Professor at the University of Washington, and Division Head at Virginia Mason Medical Center. Dr. Hillson is a licensed rheumatologist and continues to care for patients. She received her MD from Stanford School of Medicine, an MS from the California Institute of Technology, an MS in Marine Chemistry from Scripps Institute of Oceanography, and a BS from Michigan State University.
- Keith A. Katkin
-
Keith A. Katkin，2007年3月被任命为Avanir 总裁兼CEO，并当选为董事。2005年7月-2007年3月，他担任市场和销售高级副主管。加入Avanir之前，他担任Peninsula制药商业发展副主管，在公司管理方面和2005年将公司出售给Johnson & Johnson担任了重要的角色。另外，他的工作经验也包括在InterMune，安进公司和雅培公司担任领导职位。他也曾担任Cerexa制药战略顾问，2007年被森林实验室公司收购。他拥有印第安纳大学商务和会计专业学位，并且以优异的成绩获得加州大学洛杉矶分校安德森管理学院经济学工商管理硕士学位。1995年，他成为执业会计师。
Keith A. Katkin,has been a member and the Chair of Eledon Pharmaceuticals, Inc. Board since May 2017 and currently serves as the Chair of Eledon Pharmaceuticals, Inc. nominating and corporate governance committee. Mr. Katkin joined Eledon when it acquired Otic Pharma, Ltd in May 2017. Mr. Katkin served as the Principal Executive Officer and as a member of the board of directors of Urovant Sciences Ltd, a public biopharmaceutical company from September 2017 until March 2020. Mr. Katkin served as the President and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 2007 to 2016. Mr. Katkin led the growth and ultimate sale of Avanir to Otsuka Pharmaceutical Co., Ltd. for $3.5 billion. Mr. Katkin joined Avanir in 2005 as Senior Vice President of Sales and Marketing and a member of Avanir's executive management team. Prior to joining Avanir, Mr. Katkin served as Vice President, Commercial Development for Peninsula Pharmaceuticals, Inc., a privately held biopharmaceutical company, playing a key role in the concurrent initial public offering and ultimate sale of the company to Johnson and Johnson. Additionally, Mr. Katkin's employment experience includes leadership roles at InterMune, Inc., Amgen, Inc. and Abbott Laboratories. Mr. Katkin currently serves on the Board of Directors of Syndax Pharmaceuticals, Inc. and Emergent BioSolutions, Inc. Mr. Katkin has an M.B.A. from the Anderson School of Business at UCLA and earned a B.S. in Business and Accounting from Indiana University. Mr. Katkin is also a certified public accountant. - Keith A. Katkin，2007年3月被任命为Avanir 总裁兼CEO，并当选为董事。2005年7月-2007年3月，他担任市场和销售高级副主管。加入Avanir之前，他担任Peninsula制药商业发展副主管，在公司管理方面和2005年将公司出售给Johnson & Johnson担任了重要的角色。另外，他的工作经验也包括在InterMune，安进公司和雅培公司担任领导职位。他也曾担任Cerexa制药战略顾问，2007年被森林实验室公司收购。他拥有印第安纳大学商务和会计专业学位，并且以优异的成绩获得加州大学洛杉矶分校安德森管理学院经济学工商管理硕士学位。1995年，他成为执业会计师。
- Keith A. Katkin,has been a member and the Chair of Eledon Pharmaceuticals, Inc. Board since May 2017 and currently serves as the Chair of Eledon Pharmaceuticals, Inc. nominating and corporate governance committee. Mr. Katkin joined Eledon when it acquired Otic Pharma, Ltd in May 2017. Mr. Katkin served as the Principal Executive Officer and as a member of the board of directors of Urovant Sciences Ltd, a public biopharmaceutical company from September 2017 until March 2020. Mr. Katkin served as the President and Chief Executive Officer of Avanir Pharmaceuticals, Inc., a publicly traded biopharmaceutical company, from 2007 to 2016. Mr. Katkin led the growth and ultimate sale of Avanir to Otsuka Pharmaceutical Co., Ltd. for $3.5 billion. Mr. Katkin joined Avanir in 2005 as Senior Vice President of Sales and Marketing and a member of Avanir's executive management team. Prior to joining Avanir, Mr. Katkin served as Vice President, Commercial Development for Peninsula Pharmaceuticals, Inc., a privately held biopharmaceutical company, playing a key role in the concurrent initial public offering and ultimate sale of the company to Johnson and Johnson. Additionally, Mr. Katkin's employment experience includes leadership roles at InterMune, Inc., Amgen, Inc. and Abbott Laboratories. Mr. Katkin currently serves on the Board of Directors of Syndax Pharmaceuticals, Inc. and Emergent BioSolutions, Inc. Mr. Katkin has an M.B.A. from the Anderson School of Business at UCLA and earned a B.S. in Business and Accounting from Indiana University. Mr. Katkin is also a certified public accountant.
高管简历
中英对照 | 中文 | 英文- Paul Little
Paul Little于2016年11月加入公司担任首席运营官。在加入该公司之前，利特尔曾于2004年5月至2016年10月在眼力健制药公司担任多个领导职位，包括Allergan Medical Aesthetics的Vice President财务主管和商业运营主管，在那里他建立了金融和商业运营功能，包括BotoxCosmetic和Juvederm等市场领先产品。Little先生是领导团队的成员，该团队导致了关键的战略业务收购，包括Inamed，SkinMedica和Kythera Biopharmaceuticals。收购后，Little先生领导财务和商业运营整合活动。任职Allergan公司之前，Little曾任职ConAgra Foods公司10年，担任领导职务，并不断被提拔，特别是担任International Foods Group的财务Vice President，在那里他曾负责国际会计、战略和运营规划。他的职业生涯始于毕马威会计师事务所的公共会计。Little先生在加州大学圣巴巴拉分校（University of California，Santa Barbara）获得商业经济学学士学位。
Paul Little,has served as Eledon Pharmaceuticals, Inc. Chief Financial Officer since March 2021. He has over 30 years of financial, operations, business strategy and leadership experience in global public companies. Before joining Eledon in March 2021, Mr. Little served as Chief Financial Officer of Sientra Inc., a medical aesthetics company that develops and sells medical aesthetics products to plastic surgeons, where he led finance, investor relations, information technology, and manufacturing from August 2018 to March 2021. During his tenure at Sientra, Mr. Little successfully led multiple public financing rounds while strengthening the balance sheet and driving organizational and operational efficiencies to accelerate revenue growth while improving cash flow. Prior to Sientra, Mr. Little served as Chief Operating Officer for Candela Medical (formerly Syneron-Candela) from October 2016 to September 2017, where he led the Company's global supply chain and service organization and helped lead the execution of the growth strategy culminating in the sale of the company. Before Candela Medical, Mr. Little served as Vice President, Finance and Commercial Operations for Allergan PLC's Medical Aesthetics division and as a key member of the senior leadership team, helping build Allergan into the global market leader for medical aesthetics. In this role, Mr. Little built the commercial finance, commercial operations and customer operations functions from the ground up and led the financial assessment and integration of over $3B in M&A activities. He joined Allergan from ConAgra Brands, and began his career in public accounting at KPMG. Mr. Little holds a B.A. in Business Economics from the University of California, Santa Barbara.- Paul Little于2016年11月加入公司担任首席运营官。在加入该公司之前，利特尔曾于2004年5月至2016年10月在眼力健制药公司担任多个领导职位，包括Allergan Medical Aesthetics的Vice President财务主管和商业运营主管，在那里他建立了金融和商业运营功能，包括BotoxCosmetic和Juvederm等市场领先产品。Little先生是领导团队的成员，该团队导致了关键的战略业务收购，包括Inamed，SkinMedica和Kythera Biopharmaceuticals。收购后，Little先生领导财务和商业运营整合活动。任职Allergan公司之前，Little曾任职ConAgra Foods公司10年，担任领导职务，并不断被提拔，特别是担任International Foods Group的财务Vice President，在那里他曾负责国际会计、战略和运营规划。他的职业生涯始于毕马威会计师事务所的公共会计。Little先生在加州大学圣巴巴拉分校（University of California，Santa Barbara）获得商业经济学学士学位。
- Paul Little,has served as Eledon Pharmaceuticals, Inc. Chief Financial Officer since March 2021. He has over 30 years of financial, operations, business strategy and leadership experience in global public companies. Before joining Eledon in March 2021, Mr. Little served as Chief Financial Officer of Sientra Inc., a medical aesthetics company that develops and sells medical aesthetics products to plastic surgeons, where he led finance, investor relations, information technology, and manufacturing from August 2018 to March 2021. During his tenure at Sientra, Mr. Little successfully led multiple public financing rounds while strengthening the balance sheet and driving organizational and operational efficiencies to accelerate revenue growth while improving cash flow. Prior to Sientra, Mr. Little served as Chief Operating Officer for Candela Medical (formerly Syneron-Candela) from October 2016 to September 2017, where he led the Company's global supply chain and service organization and helped lead the execution of the growth strategy culminating in the sale of the company. Before Candela Medical, Mr. Little served as Vice President, Finance and Commercial Operations for Allergan PLC's Medical Aesthetics division and as a key member of the senior leadership team, helping build Allergan into the global market leader for medical aesthetics. In this role, Mr. Little built the commercial finance, commercial operations and customer operations functions from the ground up and led the financial assessment and integration of over $3B in M&A activities. He joined Allergan from ConAgra Brands, and began his career in public accounting at KPMG. Mr. Little holds a B.A. in Business Economics from the University of California, Santa Barbara.
- David Alexandre C. Gros
David AlexandreC.Gros，医学博士于2017年1月成为总裁兼首席运营官。在加入Neurocrine之前，他是高级副总裁，首席商务官和首席财务官，也是AlnylamPharmaceuticals，Inc.管理委员会的成员在2015年6月加入Alnylam之前，Gros博士曾于2011年9月至2015年6月担任赛诺菲（Sanofi SA）的执行Vice President兼首席战略官。任职Sanofi公司之前，他曾担任Centerview Partners公司（从2009年到2011年7月）、Merrill Lynch公司（从2006年到2009年）的负责生物技术和制药的投资银行职务，以及McKinsey&Company的管理咨询职务（此前）。Gros博士拥有约翰霍普金斯大学医学院的M.D.，哈佛商学院的M.B.A.和达特茅斯学院的B.A.。
David Alexandre C. Gros,has been a member of Eledon Pharmaceuticals, Inc. Board and the Company's Chief Executive Officer since September 2020. Dr. Gros served as an advisor to Eledon since May 2020. He joined Eledon from Imbria Pharmaceuticals, Inc., a clinical-stage biotechnology company, where from May 2018, he was Co-Founder, Chief Executive Officer and served on its board of directors, including as Chairman. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and of Saint Jean Groupe, S.A., a French manufacturer of pasta products. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.- David AlexandreC.Gros，医学博士于2017年1月成为总裁兼首席运营官。在加入Neurocrine之前，他是高级副总裁，首席商务官和首席财务官，也是AlnylamPharmaceuticals，Inc.管理委员会的成员在2015年6月加入Alnylam之前，Gros博士曾于2011年9月至2015年6月担任赛诺菲（Sanofi SA）的执行Vice President兼首席战略官。任职Sanofi公司之前，他曾担任Centerview Partners公司（从2009年到2011年7月）、Merrill Lynch公司（从2006年到2009年）的负责生物技术和制药的投资银行职务，以及McKinsey&Company的管理咨询职务（此前）。Gros博士拥有约翰霍普金斯大学医学院的M.D.，哈佛商学院的M.B.A.和达特茅斯学院的B.A.。
- David Alexandre C. Gros,has been a member of Eledon Pharmaceuticals, Inc. Board and the Company's Chief Executive Officer since September 2020. Dr. Gros served as an advisor to Eledon since May 2020. He joined Eledon from Imbria Pharmaceuticals, Inc., a clinical-stage biotechnology company, where from May 2018, he was Co-Founder, Chief Executive Officer and served on its board of directors, including as Chairman. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and of Saint Jean Groupe, S.A., a French manufacturer of pasta products. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.
- Steven Perrin
Steven Perrin，自2020年9月起担任Eledon Pharmaceuticals, Inc.董事会成员，当时他因与Anelixis交易有关而加入董事会。Perrin博士目前担任Eledon Pharmaceuticals, Inc.总裁兼首席科学官，自2020年9月起担任该职位。从2013年1月到加入Eledon，Perrin博士担任Anelixis Therapeutics Inc.的首席执行官。Perrin博士自2010年6月起担任ALS疗法发展研究所的执行主席。Perrin博士还在2007年1月至2018年8月期间担任ALS疗法发展研究所的首席科学官。2001年11月至2006年12月，任渤健 Idec分子谱系副总监。Perrin博士于1987年获得波士顿学院生物学理学学士学位，并于1994年获得波士顿大学医学院生物化学博士学位。
Steven Perrin,has served as a member of Eledon Pharmaceuticals, Inc. Board since September 2020, when he joined the Board in connection with the Anelixis transaction. Dr. Perrin currently serves as Eledon Pharmaceuticals, Inc. President and Chief Scientific Officer, a position he has held since September 2020. From January 2013 until joining Eledon, Dr. Perrin served as Chief Executive Officer of Anelixis Therapeutics Inc. Dr. Perrin has been Executive Chairman of the ALS Therapy Development Institute since June 2010. Dr. Perrin also served as Chief Scientific Officer for the ALS Therapy Development Institute from January 2007 to August 2018. From November 2001 to December 2006, he served as Associate Director of Molecular Profiling for Biogen Idec. Dr. Perrin received his Bachelor of Science in Biology from Boston College in 1987 and his PhD in Biochemistry from Boston University School of Medicine in 1994.- Steven Perrin，自2020年9月起担任Eledon Pharmaceuticals, Inc.董事会成员，当时他因与Anelixis交易有关而加入董事会。Perrin博士目前担任Eledon Pharmaceuticals, Inc.总裁兼首席科学官，自2020年9月起担任该职位。从2013年1月到加入Eledon，Perrin博士担任Anelixis Therapeutics Inc.的首席执行官。Perrin博士自2010年6月起担任ALS疗法发展研究所的执行主席。Perrin博士还在2007年1月至2018年8月期间担任ALS疗法发展研究所的首席科学官。2001年11月至2006年12月，任渤健 Idec分子谱系副总监。Perrin博士于1987年获得波士顿学院生物学理学学士学位，并于1994年获得波士顿大学医学院生物化学博士学位。
- Steven Perrin,has served as a member of Eledon Pharmaceuticals, Inc. Board since September 2020, when he joined the Board in connection with the Anelixis transaction. Dr. Perrin currently serves as Eledon Pharmaceuticals, Inc. President and Chief Scientific Officer, a position he has held since September 2020. From January 2013 until joining Eledon, Dr. Perrin served as Chief Executive Officer of Anelixis Therapeutics Inc. Dr. Perrin has been Executive Chairman of the ALS Therapy Development Institute since June 2010. Dr. Perrin also served as Chief Scientific Officer for the ALS Therapy Development Institute from January 2007 to August 2018. From November 2001 to December 2006, he served as Associate Director of Molecular Profiling for Biogen Idec. Dr. Perrin received his Bachelor of Science in Biology from Boston College in 1987 and his PhD in Biochemistry from Boston University School of Medicine in 1994.
- David Alexandre C. Gros
David Alexandre C. Gros，自2020年9月起担任Eledon Pharmaceuticals, Inc.董事会成员和公司首席执行官。Gros博士自2020年5月起担任Eledon的顾问。他从临床阶段的生物技术公司Imbria Pharmaceuticals，Inc.加入Eledon，从2018年5月起，他担任该公司的联合创始人、首席执行官，并在其董事会任职，包括担任董事长。在加入Imbria之前，Gros博士曾担任Neurocrine Biosciences, Inc.总裁兼首席运营官、Alnylam Pharmaceuticals, Inc.首席业务和首席财务官以及赛诺菲，S.A.首席战略官。在加入赛诺菲TERM0之前，Gros博士曾在Centerview Partners，LLC和Merrill Lynch，Pierce，Fenner & Smith Inc.担任医疗保健投资银行部门的领导职务，并在麦肯锡公司担任医疗保健咨询部门的领导职务。他此前曾在他与人共同创立的生物技术公司Eliem Therapeutics, Inc.和法国面食产品制造商Saint Jean Groupe，S.A.的董事会任职。Gros博士在约翰霍普金斯大学医学院获得医学博士学位，在哈佛商学院获得工商管理硕士学位，在达特茅斯学院获得文学学士学位。
David Alexandre C. Gros,has been a member of Eledon Pharmaceuticals, Inc. Board and the Company's Chief Executive Officer since September 2020. Dr. Gros served as an advisor to Eledon since May 2020. He joined Eledon from Imbria Pharmaceuticals, Inc., a clinical-stage biotechnology company, where from May 2018, he was Co-Founder, Chief Executive Officer and served on its board of directors, including as Chairman. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and of Saint Jean Groupe, S.A., a French manufacturer of pasta products. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.- David Alexandre C. Gros，自2020年9月起担任Eledon Pharmaceuticals, Inc.董事会成员和公司首席执行官。Gros博士自2020年5月起担任Eledon的顾问。他从临床阶段的生物技术公司Imbria Pharmaceuticals，Inc.加入Eledon，从2018年5月起，他担任该公司的联合创始人、首席执行官，并在其董事会任职，包括担任董事长。在加入Imbria之前，Gros博士曾担任Neurocrine Biosciences, Inc.总裁兼首席运营官、Alnylam Pharmaceuticals, Inc.首席业务和首席财务官以及赛诺菲，S.A.首席战略官。在加入赛诺菲TERM0之前，Gros博士曾在Centerview Partners，LLC和Merrill Lynch，Pierce，Fenner & Smith Inc.担任医疗保健投资银行部门的领导职务，并在麦肯锡公司担任医疗保健咨询部门的领导职务。他此前曾在他与人共同创立的生物技术公司Eliem Therapeutics, Inc.和法国面食产品制造商Saint Jean Groupe，S.A.的董事会任职。Gros博士在约翰霍普金斯大学医学院获得医学博士学位，在哈佛商学院获得工商管理硕士学位，在达特茅斯学院获得文学学士学位。
- David Alexandre C. Gros,has been a member of Eledon Pharmaceuticals, Inc. Board and the Company's Chief Executive Officer since September 2020. Dr. Gros served as an advisor to Eledon since May 2020. He joined Eledon from Imbria Pharmaceuticals, Inc., a clinical-stage biotechnology company, where from May 2018, he was Co-Founder, Chief Executive Officer and served on its board of directors, including as Chairman. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and of Saint Jean Groupe, S.A., a French manufacturer of pasta products. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College.
- Paul Little
Paul Little，自2021年3月起担任Eledon Pharmaceuticals, Inc.TERM1首席财务官。他在全球上市公司拥有超过30年的财务、运营、商业战略和领导经验。在2021年3月加入Eledon之前，Little先生曾担任Sientra Inc.的首席财务官，该公司是一家医疗美容公司，为整形外科医生开发和销售医疗美容产品，并于2018年8月至2021年3月期间领导财务、投资者关系、信息技术和制造等工作。在Sientra任职期间，Little先生在加强资产负债表并推动组织和运营效率的同时，成功地领导了多轮公开融资，以加速收入增长，同时改善现金流。在加入Sientra之前，Little先生于2016年10月至2017年9月担任Candela Medical（前身为Syneron-Candela）的首席运营官，在那里他领导了公司的全球供应链和服务组织，并帮助领导了增长战略的执行，最终导致公司被出售。在加入Candela Medical之前，Little先生曾担任Allergan PLC医疗美学部门的财务和商业运营副总裁，并担任高级领导团队的关键成员，帮助将Allergan打造成为医疗美学的全球市场领导者。在这个角色中，Mr. Little从头开始构建了商业金融、商业运营和客户运营职能，并领导了并购活动中超3B美元的财务评估和整合。他从康尼格拉加入艾尔建，在毕马威开始了他的公共会计职业生涯。利特尔先生拥有加州大学圣巴巴拉分校的商业经济学学士学位。
Paul Little,has served as Eledon Pharmaceuticals, Inc. Chief Financial Officer since March 2021. He has over 30 years of financial, operations, business strategy and leadership experience in global public companies. Before joining Eledon in March 2021, Mr. Little served as Chief Financial Officer of Sientra Inc., a medical aesthetics company that develops and sells medical aesthetics products to plastic surgeons, where he led finance, investor relations, information technology, and manufacturing from August 2018 to March 2021. During his tenure at Sientra, Mr. Little successfully led multiple public financing rounds while strengthening the balance sheet and driving organizational and operational efficiencies to accelerate revenue growth while improving cash flow. Prior to Sientra, Mr. Little served as Chief Operating Officer for Candela Medical (formerly Syneron-Candela) from October 2016 to September 2017, where he led the Company's global supply chain and service organization and helped lead the execution of the growth strategy culminating in the sale of the company. Before Candela Medical, Mr. Little served as Vice President, Finance and Commercial Operations for Allergan PLC's Medical Aesthetics division and as a key member of the senior leadership team, helping build Allergan into the global market leader for medical aesthetics. In this role, Mr. Little built the commercial finance, commercial operations and customer operations functions from the ground up and led the financial assessment and integration of over $3B in M&A activities. He joined Allergan from ConAgra Brands, and began his career in public accounting at KPMG. Mr. Little holds a B.A. in Business Economics from the University of California, Santa Barbara.- Paul Little，自2021年3月起担任Eledon Pharmaceuticals, Inc.TERM1首席财务官。他在全球上市公司拥有超过30年的财务、运营、商业战略和领导经验。在2021年3月加入Eledon之前，Little先生曾担任Sientra Inc.的首席财务官，该公司是一家医疗美容公司，为整形外科医生开发和销售医疗美容产品，并于2018年8月至2021年3月期间领导财务、投资者关系、信息技术和制造等工作。在Sientra任职期间，Little先生在加强资产负债表并推动组织和运营效率的同时，成功地领导了多轮公开融资，以加速收入增长，同时改善现金流。在加入Sientra之前，Little先生于2016年10月至2017年9月担任Candela Medical（前身为Syneron-Candela）的首席运营官，在那里他领导了公司的全球供应链和服务组织，并帮助领导了增长战略的执行，最终导致公司被出售。在加入Candela Medical之前，Little先生曾担任Allergan PLC医疗美学部门的财务和商业运营副总裁，并担任高级领导团队的关键成员，帮助将Allergan打造成为医疗美学的全球市场领导者。在这个角色中，Mr. Little从头开始构建了商业金融、商业运营和客户运营职能，并领导了并购活动中超3B美元的财务评估和整合。他从康尼格拉加入艾尔建，在毕马威开始了他的公共会计职业生涯。利特尔先生拥有加州大学圣巴巴拉分校的商业经济学学士学位。
- Paul Little,has served as Eledon Pharmaceuticals, Inc. Chief Financial Officer since March 2021. He has over 30 years of financial, operations, business strategy and leadership experience in global public companies. Before joining Eledon in March 2021, Mr. Little served as Chief Financial Officer of Sientra Inc., a medical aesthetics company that develops and sells medical aesthetics products to plastic surgeons, where he led finance, investor relations, information technology, and manufacturing from August 2018 to March 2021. During his tenure at Sientra, Mr. Little successfully led multiple public financing rounds while strengthening the balance sheet and driving organizational and operational efficiencies to accelerate revenue growth while improving cash flow. Prior to Sientra, Mr. Little served as Chief Operating Officer for Candela Medical (formerly Syneron-Candela) from October 2016 to September 2017, where he led the Company's global supply chain and service organization and helped lead the execution of the growth strategy culminating in the sale of the company. Before Candela Medical, Mr. Little served as Vice President, Finance and Commercial Operations for Allergan PLC's Medical Aesthetics division and as a key member of the senior leadership team, helping build Allergan into the global market leader for medical aesthetics. In this role, Mr. Little built the commercial finance, commercial operations and customer operations functions from the ground up and led the financial assessment and integration of over $3B in M&A activities. He joined Allergan from ConAgra Brands, and began his career in public accounting at KPMG. Mr. Little holds a B.A. in Business Economics from the University of California, Santa Barbara.
- Bryan Smith
Bryan Smith，自2021年4月起担任Eledon Pharmaceuticals, Inc.总法律顾问、公司秘书和首席合规官。在加入Eledon之前，Smith先生于2018年4月至2021年4月期间担任Urovant Sciences的总法律顾问、公司秘书和首席合规官，该公司是一家专注于开发泌尿系统疾病疗法的生物制药公司。在Urovant任职期间，史密斯先生带领公司完成了首次公开募股，并最终以6.81亿美元的价格出售给了Sumitovant（Sumitomo Dainippon Pharma的全资子公司）。从2011年8月到2018年4月，Smith先生在Allergan担任领导职务，担任公司泌尿科、神经科、美学和皮肤科业务部门的副总裁兼高级法律顾问和首席法律顾问。在加入艾尔建之前，史密斯先生是Gibson，Dunn & Crutcher LLP的一名诉讼律师。史密斯先生在杨百翰大学获得政治学学士学位，在南加州大学法学院获得法学博士学位。从法学院毕业后，史密斯先生是美国加利福尼亚中区地方法院尊敬的Cormac J. Carney的法律书记员。
Bryan Smith,has served as Eledon Pharmaceuticals, Inc. General Counsel, Corporate Secretary and Chief Compliance Officer since April 2021. Prior to joining Eledon, Mr. Smith was General Counsel, Corporate Secretary, and Chief Compliance Officer of Urovant Sciences, a biopharmaceutical company focused on developing therapies for urological conditions, from April 2018 to April 2021. During his time at Urovant, Mr. Smith led the company through its initial public offering and its eventual sale for $681 million to Sumitovant (a wholly owned subsidiary of Sumitomo Dainippon Pharma). From August 2011 to April 2018, Mr. Smith held leadership roles at Allergan, serving as Associate Vice President and Senior Counsel and chief counsel to the company's urology, neurology, aesthetics, and dermatology business units. Prior to joining Allergan, Mr. Smith was a litigator at Gibson, Dunn & Crutcher LLP. Mr. Smith received his B.A. in Political Science from Brigham Young University and his J.D. from the University of Southern California Law School. After graduating from law school, Mr. Smith was a law clerk to the Honorable Cormac J. Carney in the United States District Court for the Central District of California.- Bryan Smith，自2021年4月起担任Eledon Pharmaceuticals, Inc.总法律顾问、公司秘书和首席合规官。在加入Eledon之前，Smith先生于2018年4月至2021年4月期间担任Urovant Sciences的总法律顾问、公司秘书和首席合规官，该公司是一家专注于开发泌尿系统疾病疗法的生物制药公司。在Urovant任职期间，史密斯先生带领公司完成了首次公开募股，并最终以6.81亿美元的价格出售给了Sumitovant（Sumitomo Dainippon Pharma的全资子公司）。从2011年8月到2018年4月，Smith先生在Allergan担任领导职务，担任公司泌尿科、神经科、美学和皮肤科业务部门的副总裁兼高级法律顾问和首席法律顾问。在加入艾尔建之前，史密斯先生是Gibson，Dunn & Crutcher LLP的一名诉讼律师。史密斯先生在杨百翰大学获得政治学学士学位，在南加州大学法学院获得法学博士学位。从法学院毕业后，史密斯先生是美国加利福尼亚中区地方法院尊敬的Cormac J. Carney的法律书记员。
- Bryan Smith,has served as Eledon Pharmaceuticals, Inc. General Counsel, Corporate Secretary and Chief Compliance Officer since April 2021. Prior to joining Eledon, Mr. Smith was General Counsel, Corporate Secretary, and Chief Compliance Officer of Urovant Sciences, a biopharmaceutical company focused on developing therapies for urological conditions, from April 2018 to April 2021. During his time at Urovant, Mr. Smith led the company through its initial public offering and its eventual sale for $681 million to Sumitovant (a wholly owned subsidiary of Sumitomo Dainippon Pharma). From August 2011 to April 2018, Mr. Smith held leadership roles at Allergan, serving as Associate Vice President and Senior Counsel and chief counsel to the company's urology, neurology, aesthetics, and dermatology business units. Prior to joining Allergan, Mr. Smith was a litigator at Gibson, Dunn & Crutcher LLP. Mr. Smith received his B.A. in Political Science from Brigham Young University and his J.D. from the University of Southern California Law School. After graduating from law school, Mr. Smith was a law clerk to the Honorable Cormac J. Carney in the United States District Court for the Central District of California.